Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tafamidis Free Acid 12.2 mg Tablet vs Tafamidis Meglumine 20 mg Capsule
NCT04575116Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time curve from time zero to infinity at 168 hours and Maximum observed plasma concentration at 168 hours. Started Sep 2020; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04575116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575116.